A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 493 participants.
Also called NCT02302716
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 493 participants
- Registry
-
NCT02302716
-
- Other papers using this trial's data
- Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, India, Puerto Rico, Russia, South Korea, Taiwan, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02302716. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-07 (actual). Results posted on 2017-10-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
- Acronym
- ELEMENT 5
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- LY2963016
- Intervention (Drug)
- LANTUS®
- Intervention (Drug)
- Oral Antihyperglycemic Medication
- Lead sponsor
- Eli Lilly and Company
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct02302716- Content hash
25d0bbebe3bc8e0b47d83d417b704f4403203bee3ae27f8ce8d4c315cd2b5429